| Does CryoPort (CYRX) Have the Potential to Rally 54.74% as Wall Street Analysts Expect? |
The mean of analysts' price targets for CryoPort (CYRX) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-12 15:00:54 |
Czytaj oryginał (ang.) |
| Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript |
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Kyle Crews - UBS Richard Baldry - ROTH Capital David Larsen - BTIG Subbu Nambi - Guggenheim Securities Matt Stanton - Jefferies Anna Snopkowski - KeyBanc Operator Good afternoon, and welcome to Cryoport's First Quarter 2025 Earnings Call. All participants will start in a listen-only mode. |
seekingalpha.com |
2025-05-07 23:15:10 |
Czytaj oryginał (ang.) |
| CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates |
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.43 per share a year ago. |
zacks.com |
2025-05-07 22:21:12 |
Czytaj oryginał (ang.) |
| Cryoport Reports First Quarter 2025 Financial Results |
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials as of March 31, 2025 Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025 NASHVILLE, Tenn. , May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025. |
prnewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy? |
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:59 |
Czytaj oryginał (ang.) |
| Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025 |
NASHVILLE, Tenn. , April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. |
prnewswire.com |
2025-04-24 12:30:00 |
Czytaj oryginał (ang.) |
| Cryoport, Inc. (CYRX) Strategic Agreement and Transaction with DHL Group Call (Transcript) |
Cryoport, Inc. (NASDAQ:CYRX ) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Tom Heinzen - Vice President, Corporate Development & Investor Relations Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Paul Knight - KeyBanc Tejas Savant - Morgan Stanley David Larsen - BTIG David Saxon - Needham Operator Good morning, and welcome to Cryoport's Investor Conference Call. All participants will start in a listen-only mode. |
seekingalpha.com |
2025-03-31 19:11:46 |
Czytaj oryginał (ang.) |
| DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics" |
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics. |
prnewswire.com |
2025-03-31 13:06:00 |
Czytaj oryginał (ang.) |
| Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET |
NASHVILLE, Tenn. , March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025, at 8:30 a.m. |
prnewswire.com |
2025-03-31 12:09:00 |
Czytaj oryginał (ang.) |
| Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories |
NASHVILLE, Tenn. , March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. |
prnewswire.com |
2025-03-12 10:30:00 |
Czytaj oryginał (ang.) |
| Cryoport, Inc. (CYRX) Q4 2024 Earnings Call Transcript |
Start Time: 17:00 January 1, 0000 5:41 PM ET Cryoport, Inc. (NASDAQ:CYRX ) Q4 2024 Earnings Conference Call March 04, 2025, 17:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Puneet Souda - Leerink Partners David Saxon - Needham Subbu Nambi - Guggenheim David Larson - BTIG Richard Baldry - Roth Capital Kyle Crews - UBS Matt Stanton - Jefferies Operator Good afternoon, and welcome to Cryoport's Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will start in a listen-only mode. |
seekingalpha.com |
2025-03-04 22:41:06 |
Czytaj oryginał (ang.) |
| CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates |
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2025-03-04 20:35:21 |
Czytaj oryginał (ang.) |
| Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results |
FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024 NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for the fourth quarter (Q4) and year ended (FY) December 31, 2024. |
prnewswire.com |
2025-03-04 18:10:00 |
Czytaj oryginał (ang.) |
| Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 |
NASHVILLE, Tenn. , Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close. |
prnewswire.com |
2025-02-18 10:30:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 29th |
MC, LFST, EAT, CYRX and HCP have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2024. |
zacks.com |
2025-01-29 09:16:08 |
Czytaj oryginał (ang.) |
| Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies |
New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today unveiled its Cryoport Express® Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings. |
prnewswire.com |
2025-01-21 10:30:00 |
Czytaj oryginał (ang.) |
| Moffitt Cancer Center and Cryoport Announce Strategic Collaboration |
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn. |
prnewswire.com |
2025-01-14 10:30:00 |
Czytaj oryginał (ang.) |
| Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA") |
All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cryoport company and the leading global manufacturer of high-quality cryogenic freezers and dewars, has officially registered all three of its manufacturing facilities (located in Ball Ground, Georgia; New Prague, Minnesota; and Chengdu, China) with the U.S. Food and Drug Administration ("FDA"). |
prnewswire.com |
2025-01-06 10:30:00 |
Czytaj oryginał (ang.) |
| Cryoport Remains A Disappointing Prospect |
Cryoport operates in the promising life sciences sector but continues to suffer from poor fundamentals and significant cash flow challenges. Despite slight revenue growth in Q3 2024, the company remains unprofitable and has seen a drastic share price decline since my initial 'sell' rating. Recent financial improvements are minimal, with net losses narrowing and cash flow turning slightly positive, but the overall outlook remains bleak. |
seekingalpha.com |
2024-11-25 01:51:41 |
Czytaj oryginał (ang.) |
| Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe |
Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening of its newest IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium. |
prnewswire.com |
2024-11-12 10:30:00 |
Czytaj oryginał (ang.) |
| Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript |
Cryoport, Inc. (NASDAQ:CYRX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP Investor Relations and Corporate Development Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Puneet Souda - Leerink Partners Operator Good afternoon and welcome to the Cryoport Second Quarter 2024 Earnings Call. All participants will start in a listen-only mode. |
seekingalpha.com |
2024-11-09 06:54:49 |
Czytaj oryginał (ang.) |
| CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates |
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.31 per share a year ago. |
zacks.com |
2024-11-07 20:57:29 |
Czytaj oryginał (ang.) |
| Cryoport Reports Third Quarter 2024 Financial Results |
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:06:05 |
Czytaj oryginał (ang.) |
| Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024 |
NASHVILLE, Tenn. , Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close. |
prnewswire.com |
2024-10-29 10:30:00 |
Czytaj oryginał (ang.) |
| Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services |
Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell ™ Houston Facility NASHVILLE, Tenn. and HOUSTON , Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and Gulf Coast Regional Blood Center ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment. |
prnewswire.com |
2024-10-22 12:30:00 |
Czytaj oryginał (ang.) |
| TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics |
Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn. and NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and TMRW Life Sciences ("TMRW"), a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with the only FDA-cleared automated specimen management and storage platform, today announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport. |
prnewswire.com |
2024-10-21 12:30:00 |
Czytaj oryginał (ang.) |
| VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies |
Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas , Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. |
prnewswire.com |
2024-10-15 12:30:00 |
Czytaj oryginał (ang.) |
| Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus |
The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies NASHVILLE, Tenn. , Oct. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of its IntegriCell™ cryopreservation services solution provided by Cryoport Systems with the opening of its new facility located at Cryoport's integrated supply chain campus in Houston, Texas. |
prnewswire.com |
2024-10-07 12:30:00 |
Czytaj oryginał (ang.) |
| SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices |
NASHVILLE, Tenn. and RANCHO CORDOVA, Calif. |
prnewswire.com |
2024-09-25 12:30:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Is Inquiring Into Possible Securities Fraud By Cryoport Inc And Shareholders Are Encouraged To Reach Out |
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-22 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Is Looking Into Cryoport Inc For Possible Securities Law Violations And Encourages Shareholders To Help |
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-20 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Is Inquiring Into Potential Securities Law Violations By Cryoport Inc And Asks Investors To Help |
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-18 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Begins Investigation Into Cryoport Inc And Asks Shareholders To Reach Out |
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-16 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Opens Investigation Into Cryoport Inc And Encourages Shareholders To Reach Out |
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-15 23:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Shareholders To Reach Out |
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-15 02:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Initiates Probe Into Allegations Against Cryoport Inc And Motivates Its Shareholders To Contact |
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-14 03:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Reach Out |
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-13 00:00:00 |
Czytaj oryginał (ang.) |